Neos Therapeutics (NASDAQ:NEOS) posted its quarterly earnings data on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03), MarketWatch Earnings reports. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $14.80 million.
NASDAQ NEOS traded up $0.01 during trading hours on Friday, reaching $2.59. 651,079 shares of the company were exchanged, compared to its average volume of 621,268. Neos Therapeutics has a 1 year low of $2.27 and a 1 year high of $11.69. The company has a market capitalization of $83.38 million, a PE ratio of -0.97 and a beta of 0.44.
In related news, Director Alan L. Heller acquired 43,478 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The stock was acquired at an average price of $2.30 per share, for a total transaction of $99,999.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Neos Therapeutics (NEOS) Issues Earnings Results, Misses Expectations By $0.03 EPS” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3929310/neos-therapeutics-neos-issues-earnings-results-misses-expectations-by-0-03-eps.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Story: What is Cost of Debt?
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.